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economic evaluations studies published to date regarding these three drugs. 
METHODS: The economic impact was determined comparing the annual costs with 
drug and adjuvant therapy. The prices established by government for these drugs in 
renal transplantation were considered. Leaﬂet’s recommendations were followed for 
everolimus and MMF dosages. The dosage of azathioprine was based on clinical trials. 
The average cyclosporine dosages were taken according to the respective treatment 
available in clinical trials. Cochrane, Pubmed and Medline databases were used for 
pharmacoeconomic studies research. RESULTS: The most cost-saving therapy was 
found to be azathioprine, followed by everolimus, with the incremental annual cost 
of US$2862.81 (R$ 2.27/USD 1.00) compared to azathioprine. The third is MMF, 
showing US$704.69 of incremental cost compared to everolimus. According to the 
reviewed economic studies, everolimus is the most effective for the prevention/
stabilization of CAV (cardiac allograft vasculopathy) and is associated with economic 
beneﬁts due to its association with reduced hospitalization days due to Major Acute 
Cardiac Events (MACE). Both everolimus and MMF are more cost-effective than 
azathioprine in the ﬁrst 6 months after heart transplantation, with everolimus present-
ing a more favorable ratio than MMF. CONCLUSIONS: Azathioprine is the cheapest 
drug for prophylaxis of cardiac transplant rejection. However there are important 
economic studies assessing the cost beneﬁt of treatment outcome that have to be con-
sidered. One of the most important aspect is the effectiveness of preventing CAV, the 
major cause of late morbity and mortality following heart transplantation. To date, 
re-transplantation remains the only deﬁnite treatment for severe CAV, but there are 
ethical, cost concerns and poorer outcomes compared to primary transplantation that 
appear to be hurdles to re-transplantation.
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IMPACTO ECONÔMICO DA INCORPORAÇÃO DO TESTE RÁPIDO PARA 
DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA, SOB A PERSPECTIVA 
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OBJETIVOS: Avaliar o impacto econômico da incorporação do teste rápido para 
diagnóstico da insuﬁciência cardíaca (IC) em pacientes admitidos com dispnéia aguda 
em pronto atendimento. MÉTODOS: Foi desenvolvido um modelo de decisão para 
projetar os custos do diagnóstico diferencial clínico e laboratorial da IC, em pacientes 
com dispnéia aguda, no Brasil, sob a perspectiva do pagador privado, considerando 
a diretrizes locais de avaliação econômica (VIANNA, 2008). O estudo foi baseado 
nos dados clínicos publicados por JANUZZI 2005, BAGGISH 2004 e DOUST 2005, 
mostrando a importância do peptídeo natriurético B (proBNP) como marcador diag-
nóstico da IC. Os dados de custos de exames clínicos e laboratoriais, ecocardiogramas, 
taxas de sala e honorários médicos foram obtidos de fontes publicas (CBHPM 4a 
edição, PROAHSA). O horizonte de análise foi de 60 dias e nenhuma taxa de desconto 
foi adotada. Uma análise de sensibilidade univariada foi conduzida para veriﬁcar se 
os resultados eram robustos. RESULTADOS: A inclusão do teste rápido de proBNP, 
para diagnóstico da IC, proporcionou redução de 58.2% na utilização de ecocardio-
gramas, 12.6% no número de hospitalizações para esclarecimentos diagnósticos. A 
utilização do teste rápido proBNP gerou uma economia de R$ 356–10%, (custo total 
de R$ 3136 para o grupo de pacientes diagnosticados com o teste rápido e de R$ 
3493 para o grupo que utilizou-se do diagnóstico clínico). CONCLUSÕES: Os resul-
tados sugerem o marcador proBNP como uma alternativa segura e eﬁcaz no diag-
nóstico diferencial da IC, quando comparado ao diagnóstico clínico, podendo trazer 
economia de recursos para o pagador privado.
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OBJETIVOS: Avaliar o impacto econômico da incorporação do teste rápido para 
diagnóstico da insuﬁciência cardíaca (IC) em pacientes admitidos com dispnéia aguda 
em pronto atendimento. MÉTODOS: Foi desenvolvido um modelo de decisão para 
projetar os custos do diagnóstico diferencial clínico e laboratorial da IC, em pacientes 
com dispnéia aguda, no Brasil, sob a perspectiva do pagador público, considerando a 
diretrizes locais de avaliação econômica (VIANNA, 2008). O estudo foi baseado nos 
dados clínicos publicados por JANUZZI 2005, BAGGISH 2004 e DOUST 2005, 
mostrando a importância do peptídeo natriurético B (proBNP) como marcador diag-
nóstico da IC. Os dados de custos de exames clínicos e laboratoriais, ecocardiogramas, 
taxas de sala e honorários médicos foram obtidos de fontes públicas (SAI/SUS e 
DATASUS). O horizonte de análise foi de 60 dias e nenhuma taxa de desconto foi 
adotada. Uma análise de sensibilidade univariada foi conduzida para veriﬁcar se os 
resultados eram robustos. RESULTADOS: A inclusão do teste rápido de proBNP, 
para diagnóstico da IC, proporcionou redução de 58.2% na utilização de ecocardio-
gramas, 12.6% no número de hospitalizações para esclarecimentos diagnósticos. O 
custo total por paciente para o grupo que utilizou o teste rápido proBNP foi de R$ 
652.04 e de R$ 659.53 para o grupo que utilizou-se do diagnóstico clínico da IC. 
CONCLUSÕES: Os resultados sugerem o marcador proBNP como uma alternativa 
segura e eﬁcaz no diagnóstico diferencial da IC, quando comparado ao diagnóstico 
clínico, podendo trazer economia de recursos para o SUS.
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OBJECTIVES: The main objective of this analysis was to determine direct medical 
costs for pulmonary embolism (PE) in patient undergoing elective total hip replace-
ment (THR) in Slovakia from the payer perspective in 2007. METHODS: A retrospec-
tive cost of illness analysis of PE in patients undergoing elective THR during 2007 
was realized from the health insurance company perspective. Data for used resources 
and respective costs were collected from the database of the biggest health insurance 
company in Slovakia. Costs in Euro were calculated with ofﬁcial exchange rate 30,126 
Sk/a Comparison of costs between group of patients with PE and group without PE 
was done. RESULTS: The group of 2153 patients (845 men and 1 308 women) with 
elective THR was analyzed. The average age was 64.5 years (63.3 in men and 65.2 
in women). Within this group there were 11 cases of PE (average age 66.4). Average 
direct medical costs for group of patients WITH and WITHOUT pulmonary embolism 
were a2513 and a1579 respectively, with the following structure of costs: inpatient—
a2167 and a1265; drugs—a79 and 1a16; examinations and treatments during 
 inpatient stay (SVALZ)—a198 and a131; outpatient—a69 and a67 respectively. 
CONCLUSIONS: Average direct medical costs for patients with PE after elective THR 
are a2513. This is almost 60% more then the average direct medical costs for patients 
without PE. Main driver of increased costs is inpatient stay at intensive care unit and 
at internal medicine department after episode of pulmonary embolism.
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PACIENTES AMBULATORIAIS MEDICADOS COM ANTI-HIPERTENSIVOS
Wadt M1, Zanini AC2
1Universidade Paulista, Valinhos, São Paulo, Brazil, 2Faculdade de Medicina, São Paulo, Brazil
OBJETIVOS: Avaliar o perﬁl epidemiológico de medicamentos prescritos para paci-
entes ambulatoriais com hipertensão arterial sistêmica (HAS). MÉTODOS: Em popu-
lação com acesso à medicina complementar e benefício medicamento através de um 
PBM foi feito análise retrospectiva do consumo entre 2003 e 2008. Apenas para o 
ano de 2008, foi feita análise utilizando dados de 13.114 usuários. Os pacientes foram 
agrupados por nível de adesão ao tratamento em função do registro mensal de 
aquisições; usuários com aquisições em pelo menos 10 meses no ano foram consid-
erados para avaliação de uso e de co-morbidades. Foram adotadas as referências de 
DDD (dose diária deﬁnida) preconizadas pelo ATC-Index. RESULTADOS: O perﬁl 
de consumo ao longo de cinco anos aponta forte tendência de uso de bloqueadores 
de receptores de angiotensina II e de produtos com associação de fármacos. A comer-
cialização dos medicamentos amostrados pela PBM variou 14,7% no período, 
enquanto o INPC foi e 20,1%, e menor que outros índices do setor saúde. No que 
diz respeito ao perﬁl epidemiológico, observou-se alta adesão (10, 11 ou 12 meses no 
ano) em 9,0% dos usuários, e a adesão mediana (7, 8 e 9 meses no ano) por 9.5%. 
A maioria, de 81.5% adquiriu medicamentos por 6 meses ou menos. No grupo com 
alta adesão, 1,184 pacientes (51.6%) apresentaram co-morbidade com hiperlipide-
demia e/ou diabetes melitos; destes e 168 (14.2%) consumiram medicamentos para as 
três patologias. Em média, o grupo consumiu 2.2 DDD, 2.1 entre mulheres e 2.3 entre 
homens, ao custo diário médio de R$ 1.91. CONCLUSÕES: Em pacientes hipertensos, 
dos quais 611 medicados para co-morbidades, os resultados, da análise econômica 
durante 6 anos mostram que a administração de benefícios reduziu o preço médio dos 
medicamentos por dose padrão.
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OBJECTIVES: Estimate the economic value of heart rate (HR) control in stable angina 
(SA) patients in the perspective of the Brazilian Public Health System (Sistema Único 
de Saúde—SUS). METHODS: A Markov chain Monte Carlo stochastic simulation 
model was used to estimate the inﬂuence of HR in cardiovascular (CV) morbidity and 
mortality and its economic consequences to SUS. Resting HR distribution was mod-
elled as a gamma function. Overall survival and time to hospitalization were modelled 
with weibull survival functions. Only CV events (acute myocardial infarction, stroke, 
heart failure and death) and revascularization procedures (coronary artery bypass graft 
and percutaneous coronary interventions) costs were considered. Brazil’s health 
context was taken into account, including baseline characteristics of SA patients, 
resource utilization and direct costs (no indirect costs were included), reﬂecting SUS 
perspective. Annual discount rate was 5% and time horizon 20 years. RESULTS: 
Reduction in SUS direct costs, per patient, would range from R$147 (95%CI  
[R$136; R$159]) to R$354 (95%CI  [R$321; R$388]) for each 5 bpm decrease in 
HR up to 20 bpm, 70% of these costs reductions resulting from avoidable revascu-
larization procedures. In patients with HR  70 bpm (average HR: 87 bpm), a 10 or 
20 bpm HR reduction would decrease SUS per patient average direct cost by R$404 
(95%CI  [R$393; R$415]) or by R$611 (95%CI  [R$598; R$625]), respectively. 
Only 33% of the 2.5 million Brazilian SA patients take beta-blockers and might 
potentially have the recommended resting HR (50–60 bpm). Thus, a 10 bpm reduction 
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from the average HR for the overall SA population (74 bpm) could reduce SUS direct 
cost by over R$450 million. CONCLUSIONS: These results show that effective lower-
ing heart rate strategies may contribute to substantial savings of public funds in Brazil. 
Therefore, heart rate must be regarded as an important CV risk factor from an eco-
nomic point of view.
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OBJECTIVES: To assess the cost effectiveness of rivaroxaban against enoxaparin for 
the prevention of venous thromboembolism (VTE) in patients undergoing total hip 
replacement (THR) or total knee replacement (TKR) in a Colombian setting. 
METHODS: A cost-effectiveness model was developed to assess the cost effectiveness 
of rivaroxaban compared to enoxaparin in a Colombian setting over a 5-years time 
horizon. The model was divided into three modules: prophylaxis, post-prophylaxis, 
and long-term complications. The ﬁrst two modules constitute the acute phase and 
were represented in a decision tree while the long-term complications module was 
developed as a Markov process. Efﬁcacy and safety parameters used in the prophylaxis 
module were derived from the RECORD trials in the prevention of VTE following 
THR or TKR. Published epidemiological and clinical data were used to estimate the 
risk of VTE and other long term complications beyond the trial period. The analysis 
was performed from a health care payer’s perspective. Cost data was based on clinical 
guidelines, product labels, nationally and locally published sources, and expert 
opinion. VTE related utilities reported in literature were used in this analysis. One-way 
and probabilistic sensitivity analyses were performed in order to address uncertainty 
around the model inputs. RESULTS: Rivaroxaban dominated enoxaparin, yielding 
improved health outcomes (QALYs) and savings of COP 114,345 per patient in THR. 
Savings were driven mainly by reduced outpatient administration costs. Rivaroxaban 
also dominated enoxaparin with savings of 152,484 COP in TKR patients. Probabi-
listic sensitivity analyses showed dominance in 89% of cases in THR and in 99% in 
TKR. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to enoxaparin for 
the prevention of VTE following THR or TKR in Colombia.
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BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
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OBJECTIVES: To develop a cost-effectiveness analysis of dabigatran etexilate versus 
enoxaparin for the prevention of venous thromboembolism after total hip replacement 
under the Brazilian public health care system perspective. METHODS: A decision tree 
analysis was developed for the ﬁrst 180 days, considering the occurrence of deep vein 
thrombosis (DVT), pulmonary embolism (PE) and all-cause mortality, followed by 
two Markov models, for post-thrombotic syndrome and thromboembolic pulmonary 
hypertension. Long term costs and outcomes associated with the prevention of venous 
thromboembolism in patients receiving dabigatran or enoxaparin were, therefore, 
projected. The cycle duration was 1 month and the corresponding transition probabili-
ties were obtained from the RE-NOVATE study. The outcomes were expressed as the 
incremental number of all thromboembolic events and deaths related to the surgical 
procedure and its acute and late complications. The analysis considered only direct 
medical costs. Unit costs for drugs and procedures were obtained from Kairos 
 Magazine (ex-factory price) and the National Database of Ambulatory Costs 
(SIA/DATASUS), respectively. Costs and outcomes were discounted at an annual 5% 
discount rate. A budget impact analysis was developed, considering the estimated 
number of total hip arthroplasties in the Brazilian public health care system in 2009. 
Main parameters were evaluated in a sensitivity analysis. RESULTS: After a literature 
review, the evidences showed similar effectiveness between both treatments. Total 
costs associated with dabigatran and enoxaparin were BRL667 (US$476) and 
BRL1,097 (US$784), respectively. The prophylaxis cost reduction was BRL430 
(US$307), in favor of dabigatran. In 2009, total annual costs estimated for dabigatran 
and enoxaparin were BRL7,425,815 (US$5,304,154) and BRL12,222,284 
(US$8,730,203), respectively, with a negative budget impact of BRL4,796,469. (2005 
purchasing power parity index 1USD  1.4BRL) CONCLUSIONS: Dabigatran 
showed to be as effective as enoxaparin and cost-saving for the prevention of venous 
thromboembolism after total hip replacement under the Brazilian public health care 
system perspective.
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OBJECTIVES: This study was designed to evaluate the cost-effectiveness of diagnostic 
assessment guided to B-Type Natriuretic Peptide compared with clinical judgment 
alone, in acute dyspnea, in the Uniﬁed Health System Scenario. METHODS: A Deci-
sion Analytic Model was developed to evaluate the cost-effectiveness of diagnostic 
assessment guided to B-Type Natriuretic Peptide compared with clinical judgment 
alone. We used effectiveness data described in a randomized, controlled clinical trial 
and data from ambulatory and hospital treatment costs coming from Brazilian studies 
on costs of Heart Failure. The effectiveness units were “hospital admissions avoided” 
and “echocardiography avoided”, at 60 days. The decision tree and statistical analyses 
were performed by the software TreeAge Pro Healthcare. RESULTS: The use of B-
Type Natriuretic Peptide in the diagnostic assessment of patients with acute dyspnea 
showed a reduction of echocardiography (-58.2%) and hospital admissions (-12.6%), 
when compared to the clinical judgment alone. The average cost per patient of B-Type 
Natriuretic Peptide group was BRL 652 (US$465) versus BRL 659 (US$470) of clinical 
group (2005 purchasing power parity index 1 USD  1.4 BRL*). CONCLUSIONS: 
We concluded that use of B-Type Natriuretic Peptide can be cost saving strategy, in 
the diagnostic assessment of patients presenting to acute care settings with dyspnea, 
in Uniﬁed Health System.
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OBJECTIVES: Clinical evidence has demonstrated that considerable differences exist 
among various ARBs in terms of safety and efﬁcacy. These differences can lead to 
diverse economic outcomes depending on the chosen intervention. This analysis was 
aimed to assess the cost-effectiveness of ARBs available in the Colombian market. 
METHODS: We performed a cost-effectiveness ratio analysis of ARBs in Colombia. 
A systematic review was performed on available evidence. Head-to-head studies com-
paring Irbesartan with other ARBs were included and costs were evaluated based on 
a Colombian pricelist publication. Cost-effectiveness ratio was ﬁnally calculated with 
the efﬁcacy of interventions (systolic and diastolic mmHg reduction) in the analyzed 
trials. A sensitivity analysis was performed. RESULTS: Based on Mancia et al. 
[BloodPressMonit 2002;7: 135–42] and drug cost in the Colombian market, cost-
effectiveness for Irbesartan 150 mg was U$10.42 per mmHg reduced in systolic blood 
pressure (SBP) and US$18 for diastolic blood pressure (DBP) compared with US$18.53 
in DBP and US$28.72 for SBP with Valsartan (80 mg). According to Bobrie et al. 
[AmJHypertens 2005;18:1482–8] the cost effectiveness ratio for Irbesartan/Hydro-
chlorothiazide was US$8.97 (SBP) and US$12.28 (DBP) per mmHg reduced compared 
with US$12.72 (SBP) and US$18.22 (DBP) for Valsartan/Hydrochlorothiazide. The 
results based on Oparil et al. [JClinH 2001;3:283–318] were US$13.26 (SBP) U$17.81 
(DBP) for Irbesartan 150 mg compared with U$19.09 (SBP) US$28.27 (DBP) for 
Losartan 50 mg. Results from analysis performed with Kassler-Taub [AJH 
1998;11:445–53] were US$820 (SBP) and U$11.50 (DBP) for Irbesartan 300 mg 
compared with US$13.41 (SBP) and $17.41 (DBP) for Losartan 100 mg. Finally, based 
on the Negro et al. [JEndocrinolInvest. 2006;29:957–61] the results were $23.02 (SBP) 
and US$30.42 (DBP) compared with US$27.95 (SBP) US$32.67 (DBP) for Telmisartan 
80 mg. CONCLUSIONS: This analysis shows that ARBs have different economic 
outcomes regarding hypertension treatment. Irbesartan shows a good cost-effective-
ness ratio compared with other ARBs in the Colombian context.
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VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS 
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THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
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OBJECTIVES: To develop a cost-effectiveness analysis of dabigatran etexilate versus 
enoxaparin for the prevention of venous thromboembolism after total knee replace-
ment, under the Brazilian public health care system perspective. METHODS: A deci-
sion tree analysis was developed for the ﬁrst 180 days, considering the occurrence of 
deep vein thrombosis (DVT), pulmonary embolism (PE) and all-cause mortality, fol-
lowed by two Markov models, for post-thrombotic syndrome and thromboembolic 
pulmonary hypertension. Long term costs and outcomes associated with the preven-
tion of venous thromboembolism in patients receiving dabigatran or enoxaparin were, 
therefore, projected. The cycle duration was 1 month and the corresponding transition 
probabilities were obtained from the RE-MODEL study. The outcomes were expressed 
as the incremental number of all thromboembolic events and deaths related to the 
surgical procedure and its acute and late complications. The analysis considered only 
direct medical costs. Unit costs for drugs and procedures were obtained from Kairos 
Magazine (ex-factory price) and the National Database of Ambulatory Costs 
(SIA/DATASUS), respectively. Costs and outcomes were discounted at an annual 5% 
discount rate. A budget impact analysis was developed, considering the estimated 
number of total knee arthroplasties in the Brazilian public health care system in 2009. 
Main parameters were evaluated in a sensitivity analysis. RESULTS: After a literature 
review, the evidences showed similar effectiveness between both alternatives. Total 
costs associated with dabigatran and enoxaparin were BRL279 (US$199) and BRL451 
(US$322), respectively. The prophylaxis cost reduction was BRL172 (US$123), in 
favor of dabigatran. In 2009, total annual costs estimated for dabigatran and enoxa-
parin were BRL1,113,412 (US$795,294) and BRL1,800,886 (US$1,286,347), respec-
tively, with a negative budget impact of BRL687,474 (US$491,053). (2005 purchasing 
power parity index 1USD  1.4BRL) CONCLUSIONS: Dabigatran showed to be as 
